Arbro Pharmaceutical Limited (India) Grants Vanguard Pharmaceutical Corp. Exclusive Long Term Selling Contract in Latin

SAN ANTONIO, TX, Jul 31 (MARKET WIRE) --
Vanguard Pharmaceutical Corp., (PINKSHEETS: VGPH) -- a company providing
the market with affordable and safe generic medicines has been granted a
10 year exclusive sales contract from Arbro Pharmaceutical Limited for
the sale of its pharmaceutical products in Latin America and the
Caribbean.

Arbro has over 150 generic drugs that are regularly exported, is
internationally accredited for Good Manufacturing Practices (GMP), follows
the WHO guidelines, and is ISO 9001-2000 certified. Further, its internal
testing labs provide a high standard of quality control and bioequivalence
accreditation.

Vanguard's strategic alliance with Arbro will ensure delivery of high
quality products at affordable prices. Vanguard has performed a market
price analysis of Arbro's drugs in Brazil, Peru, and Paraguay and has
found their prices to be significantly lower than recent tenders granting
them a huge opportunity in these countries.

www.vanguardpharm.com

About Vanguard Pharmaceutical

In an era of ageing populations and rising health care costs. Vanguard's
mission is to provide the market with drugs they can afford and with an
assurance of its quality. To provide the market with affordable and safe
drugs, Vanguard has focused on generic medicines. Generic medicines allow
patients to access safe, effective, high-quality medicines at 10%-80% of
the price of branded originator medicines. In this way, generic medicines
support the sustainability of health care provision and contribute to
controlling pharmaceutical expenditure.

Vanguard's main stream of business is the sale of generic drugs. It is
currently targeting Latin America as it is believed to have a
substantially unmet demand for advanced generics. The region is set to
emerge as a globally significant market and its generics market is
conservatively expected to reach US$6.4 billion by the year-end of 2009.
Through its R&D facilities, Vanguard will strive to increase its generic
product line further allowing them to penetrate Latin America and, in the
future, expand into other geographic markets such as North America and
Europe.

Forward Looking Statements

This press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements in this release that are forward-looking statements are based
on current expectations and assumptions that are subject to known and
unknown risks, uncertainties, or other factors which may cause actual
results, performance, or achievements of the company to be materially
different from any future results, performance, or achievements expressed
or implied by such forward-looking statements. Actual results could
differ materially because of factors such as the effect of general
economic and market conditions, entry into markets with vigorous
competition, market acceptance of new products and services, continued
acceptance of existing products and services, technological shifts, and
delays in product development and related product release schedules, any
of which may cause revenues and income to fall short of anticipated
levels. All information in this release is as of the date of this
release. The company undertakes no duty to update any forward-looking
statement to conform the statement to actual results or changes in the
company's expectations.

Contact:
Francine Peres
210-215-4633
President
Vanguard Pharmaceutical Corp.
www.vanguardpharm.com

Copyright 2008, Market Wire, All rights reserved.

-0-